Why Femasys Inc.’s (FEMY) Stock Is Up 5.25%
As of Monday, December 15, Femasys Inc.’s FEMY share price has surged by 5.25%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women’s reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women’s healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Commentary & Analysis
Why Femasys Inc.’s (FEMY) Stock Is Down 5.66%
As of Monday, December 08, Femasys Inc.’s FEMY share price has dipped by 5.66%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Femasys Inc.’s (FEMY) Stock Is Up 5.28%
As of Thursday, December 04, Femasys Inc.’s FEMY share price has surged by 5.28%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Femasys Inc.’s (FEMY) Stock Is Down 5.21%
As of Wednesday, December 03, Femasys Inc.’s FEMY share price has dipped by 5.21%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Femasys Inc.’s (FEMY) Stock Is Down 7.86%
As of Monday, December 01, Femasys Inc.’s FEMY share price has dipped by 7.86%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | FEMY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8.9 | $422.9 | 6% |
|
| Shares Out (Mil) | 3.9 | 41.4 | 11% |
|
| Institutional Ownership | 88.5% | 83.6% | 56% |
|
| Float (Mil) | 1.8 | 34.9 | 5% |
|
| Beta | na | 0.88 | na |
|
| Avg Daily Volume (000s) | 4,025 | 409 | 91% |
|
| Price Change (52-week) |
(76.2%) | 66.3% | 7% |
|
| Growth | FEMY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 18.1% | 11.9% | 78% |
|
| Net Income (5yr) | (21.9%) | (5.9%) | 18% |
|
| EPS (5yr) | 42.0% | 10.4% | 89 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.4% | (16.2%) | 74% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | na | 2 | |
| Current EPS | ($0.600) | ($2.570) | ($2.125) | |
| Month Ago EPS | ($1.500) | ($5.000) | ($5.800) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($1.500) | ($5.000) | ($5.800) | |
| Year/Year Chg | (814.3%) | (72.7%) | (83.3%) | |
| Financials | FEMY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $123 | 4% |
|
| Net Income (TTM) (Mil) | ($12) | ($9) | 28% |
|
| EPS (TTM) | ($4.969) | ($0.400) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($18) | ($3) | 15% |
|
| Net Cash Flow (TTM) (Mil) | $2 | $1 | 47% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $22 | 23% |
|
| Enterprise Value (Q1) (Mil) | $8 | $418 | 7% |
|
| Valuation | FEMY | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.23 | 3.13 | 30% |
|
| P/E | na | 28.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.7 | na |
|
| Ratios | FEMY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 60.9% | 58.7% | 73% |
|
| Net Margin | (511.8%) | (6.9%) | 2% |
|
| ROA | (79.8%) | (12.3%) | 7% |
|
| ROE | (256.0%) | (12.3%) | 3% |
|
| Liabilities to Assets | 55.8% | 46.0% | 48% |
|
| F-Score | 3 | 4 | 18% |
|
Femasys Inc. did not pass any screens on 8/21/2026.
